Takeda files for approval of alogliptin-metformin combination tablet

U.S. subsidiary of Japanese drug maker submits application to FDA

OSAKA, Japan — A U.S. subsidiary of Takeda Pharmaceutical has filed for regulatory approval of a drug designed to treat Type 2 diabetes, the company said.

The Takeda Global Research and Development Center filed with the Food and Drug Administration for approval of an alogliptin-metformin combination tablet. The company expects the FDA to review the application within the next 10 months.

"This [new drug application] submission further extends Takeda's commitment to offering patients with Type 2 diabetes a range of therapeutic options to help them manage their condition," Takeda Global Research and Development Center VP clinical science Thomas Strack said. "The worldwide incidence of Type 2 diabetes continues to expand at a rapid rate, and we continue our research into additional medicines to treat these patients."

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

Login or Register to post a comment.